Valeant’s multiple organ failure puts it in ICU

March 21, 2016

The beleaguered drugmaker has found accounting improprieties. It is booting CEO Mike Pearson but ex-CFO Howard Schiller has refused to quit as a director. The board, the numbers and the strategy are fractured. Some $30 bln of debt means Valeant risks an Enron or WorldCom endgame.

Viewsroom: Valeant spiral, Chinese tourists, top-court pick

March 18, 2016

The funky pharma firm is coming to grips with mortality, while China's Anbang gobbles up U.S. hotels at high prices. Plus: Corporate America gets a Supreme Court nominee it can live with.

from Viewsroom:

Viewsroom: Wall Street frenemies, Ackman, AT&T

March 4, 2016

Trump and Hillary Clinton bash banks while taking their money, and the controversial investor sticks it out at Valeant and Herbalife. Plus: aging telecoms shake up cable TV.

Ackman inadvertently makes case for index funds

January 28, 2016

The Pershing Square boss rails against passive portfolio managers in his latest missive. Bill Ackman also blames his own woeful 2015 performance on bad market timing and hedges that didn’t work. That encapsulates why most investors should stick to the likes of the S&P 500.

Contortions make rail deal tough sell for Ackman

December 8, 2015

A revised offer from Canadian Pacific for Norfolk Southern, together worth nearly $50 bln, included an interim trust, less cash and finger-in-the-air merger math. The activist contributed 23 pages of slides. NS was too quick to rebuff it. Investors, though, may just be confused.

Bill Ackman pushes limits of activism at Valeant

November 5, 2015

The hedge fund boss hinted the drugmaker’s CEO may need to go and was invited into the boardroom mid-crisis, according to a newspaper report. Ackman also seems to have usurped Valeant’s defense. The $55 bln of quickly lost market value suggests his involvement isn’t helping much.

Ackman’s Valeant defense nervy but unpersuasive

October 30, 2015

The hedge fund founder says the drug firm is a victim of bad PR, naive investors and jealous rivals. He even likened his stake to Warren Buffett’s savvy investment in lenders cheated by a 1960s salad-oil scandal. The reality is Valeant is flawed in ways a “pep talk” won’t fix.

Valeant sets tone for post-M&A accounting scrutiny

October 22, 2015

The drugmaker’s stock ended Wednesday down 19 pct after a short-seller and others questioned its bookkeeping. The $40 bln serial acquirer’s history may make it an obvious target, but as growth and mergers slow a renewed investor focus on companies’ figures is a logical shift.

Valeant’s platform trembles beneath Ackman’s feet

October 19, 2015

The hedge fund manager bought a 5.5 pct stake because Valeant offered a cure for poor capital allocation by drugmakers. Now it’s scaling back on acquisitions, raising R&D and limiting price increases. The outsiders missed the political benefits to pharma’s spending.

Valeant urges $54 bln deal with carrot, two sticks

June 2, 2014

The acquisitive pharma group raised its offer for Allergan again, if the Allergan board cooperates. Meanwhile hedgie Bill Ackman is threatening to unseat six directors – and Valeant could yet decide to go fully hostile. But questions over Valeant’s own stock remain its weakness.